Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ginkgo Bioworks Hldgs Inc (NY: DNA )

1.235 +0.035 (+2.92%)
Streaming Delayed Price Updated: 9:46 AM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ginkgo Bioworks Hldgs Inc

< Previous 1 2 3 4 5 6 Next >
This Growth Stock Is Down 63% in 1 Year. Here's Why You Should Buy the Dip and Hold It for 5 Years
The bear market hasn't been kind, but the future could be a lot better. 
Via The Motley Fool
Luminar Technologies, EHang Holdings And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
7 Penny Stocks With Massive Growth Potential
If you laugh at red ink, these tempting ideas just might be for you. 
Via InvestorPlace
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Ginkgo Bioworks Holdings's Earnings: A Preview
 
Via Benzinga
Buy the Dip: 2 Exceptional Growth Stocks to Grab Before the Next Bull Market
Now's the time to load up on stocks that got dented in the bear market. 
Via The Motley Fool
This Biotech Is Already Using AI, but Is the Growth Stock a Buy?
Few biotechs can claim to be using AI in as central of a role as Ginkgo Bioworks. 
Via The Motley Fool
Is It Too Early to Invest in Ginkgo Bioworks?
Ginkgo is on track to easily beat its guidance for 2022. But what about its bottom line? 
Via The Motley Fool
2 Bruised Growth Stocks to Buy While They're Cheap
Both are on the verge of fast growth, and they haven't had any major setbacks yet. 
Via The Motley Fool
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
Biotech stocks were hard-hit in 2022, but these disruptive names in the field of synthetic biology can be big winners in 2023. 
Via InvestorPlace
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
These stocks are risky. But they just might deliver huge gains if analysts are right. 
Via The Motley Fool
Cathie Wood Keeps Buying Ginkgo Bioworks (DNA) Stock
Ginkgo Bioworks has tumbled this week, but Cathie Wood is among the key buyers of DNA stock, picking up shares yesterday. 
Via InvestorPlace
3 Penny Stocks That Could Rise 500% in 2023
Tilt the odds in your favor in 2023 with some of these high-potential penny stocks. The risks are high, but so are the rewards. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 35 companies reached new 52-week lows. 
Via Benzinga
What You Missed On Wall Street On Friday
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
Three Pharma Stocks to Sell Before They Die
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January. 
Via InvestorPlace
Down 76% This Year, Is This Growth Stock Now a Screaming Buy?
The company's strategy will take time to implement, but it'll make investors a lot richer if it works. 
Via The Motley Fool
Analyzing Ginkgo Bioworks Holdings's Short Interest
Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has fallen 7.31% since its last report. The company recently reported that it has 134.22 million shares sold short, which is 14.71% of all... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
 
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These two companies are facing short-term issues that are likely to give way to long-term success. 
Via The Motley Fool
Looking Into Ginkgo Bioworks Holdings's Recent Short Interest
Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has fallen 14.12% since its last report. The company recently reported that it has 134.22 million shares sold short, which is 15.87% of all... 
Via Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
Target, Holley, Ferroglobe And Other Big Losers From Wednesday
U.S. stocks closed mostly lower on Wednesday, with the Nasdaq Composite dropping around 175 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Ginkgo Bioworks Stock Is Sliding Wednesday Morning
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower by 8.63% to $2.44 Wednesday morning. The company during Tuesday's after-hours session announced a public offering of Class A common... 
Via Benzinga
Carnival, Ginkgo Bioworks And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Ginkgo Bioworks Stock Is Down After Hours: What's Happening?
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Tuesday's after-hours session after the company announced a proposed public offering. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.